Your browser doesn't support javascript.
loading
Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies.
Hadjadj, Jérôme; Guffroy, Aurélien; Delavaud, Christophe; Taieb, Guillaume; Meyts, Isabelle; Fresard, Anne; Streichenberger, Nathalie; L'Honneur, Anne-Sophie; Rozenberg, Flore; D'Aveni, Maud; Aguilar, Claire; Rosain, Jérémie; Picard, Capucine; Mahlaoui, Nizar; Lecuit, Marc; Hermine, Olivier; Lortholary, Olivier; Suarez, Felipe.
Afiliación
  • Hadjadj J; Department of Haematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, France et Université Paris Descartes, 149 rue de Sèvres, 75015, Paris, France.
  • Guffroy A; Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Delavaud C; Department of Adult Radiology, Necker Hospital, Paris, France.
  • Taieb G; Department of Neurology, CHU Montpellier, Hôpital Guy de Chauliac, Montpellier, France.
  • Meyts I; Department of Microbiology and Immunology, Childhood Immunology, KU Leuven, Leuven, Belgium.
  • Fresard A; Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
  • Streichenberger N; Department of Infectious Diseases, CHU Saint-Etienne, Saint-Etienne, France.
  • L'Honneur AS; Department of Pathology - Université Claude Bernard Lyon1 - Institut NeuroMyogène CNRS UMR 5310 - INSERM U1217, Hospices Civils de Lyon, Lyon, France.
  • Rozenberg F; Department of Virology, Université Paris Descartes et Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  • D'Aveni M; Department of Virology, Université Paris Descartes et Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  • Aguilar C; Department of Hematology, University Hospital, Nancy, France.
  • Rosain J; Sorbonne Paris Cité, Necker Pasteur Center for Infectious Diseases and Tropical Medicine, APHP-Hôpital Necker-Enfants Malades, IHU Imagine, Université Paris Descartes, Paris, France.
  • Picard C; Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Hôpital Universitaire Necker-Enfants Malades, Paris Descartes University, Paris, France.
  • Mahlaoui N; Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris (APHP), Necker Medical School, Paris, France.
  • Lecuit M; Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris (APHP), Necker Medical School, Paris, France.
  • Hermine O; INSERM U1163 & CNRS ERL 8254, Institut Imagine, Sorbonne Paris Cité, Paris, France.
  • Lortholary O; Pediatric Immuno-Haematology and Rheumatology Unit, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Suarez F; Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Hôpital Universitaire Necker-Enfants Malades, Paris Descartes University, Paris, France.
J Clin Immunol ; 39(1): 55-64, 2019 01.
Article en En | MEDLINE | ID: mdl-30552536
ABSTRACT

PURPOSE:

Progressive multifocal leukoencephalopathy (PML) is a rare but severe demyelinating disease caused by the polyomavirus JC (JCV) in immunocompromised patients. We report a series of patients with primary immune deficiencies (PIDs) who developed PML.

METHODS:

Retrospective observational study including PID patients with PML. Clinical, immunological, imaging features, and outcome are provided for each patient.

RESULTS:

Eleven unrelated patients with PIDs developed PML. PIDs were characterized by a wide range of syndromic or genetically defined defects, mostly with combined B and T cell impairment. Genetic diagnosis was made in 7 patients. Before the development of PML, 10 patients had recurrent infections, 7 had autoimmune and/or inflammatory manifestations, and 3 had a history of malignancies. Immunologic investigations showed CD4+ lymphopenia (median 265, range 50-344) in all cases. Six patients received immunosuppressive therapy in the year before PML onset, including prolonged steroid therapy in 3 cases, rituximab in 5 cases, anti-TNF-α therapy, and azathioprine in 1 case each. Despite various treatments, all but 1 patient died after a median of 8 months following PML diagnosis.

CONCLUSION:

PML is a rare but fatal complication of PIDs. Many cases are secondary to immunosuppressive therapy warranting careful evaluation before initiation subsequent immunosuppression during PIDs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucoencefalopatía Multifocal Progresiva / Síndromes de Inmunodeficiencia Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Immunol Año: 2019 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucoencefalopatía Multifocal Progresiva / Síndromes de Inmunodeficiencia Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Immunol Año: 2019 Tipo del documento: Article País de afiliación: Francia